Gilead to Present New Antiviral Data at IDWeek 2026 Amid Upcoming Q3 Earnings

Gilead Sciences (Nasdaq: GILD) is set to deliver fresh insights into its antiviral and HIV research portfolio this week, presenting data at IDWeek 2026 from October 21 to 24. Meanwhile, the company is gearing up to release its third-quarter 2026 financial results on October 29 after market close, setting the stage for what may be a pivotal earnings report.

New Data Highlights at IDWeek 2026

On October 19, Gilead announced it will present new data across HIV and emerging antiviral research at IDWeek 2026, a prominent industry conference. The program includes several studies previously unreported publicly .

One notable development expected to be shared is the final Phase 1b results for GS‑1179 (formerly ABI‑1179), an investigational long‑acting treatment for recurrent genital herpes. According to a community report, this candidate may offer the potential for once‑weekly oral dosing—marking a significant convenience leap over traditional daily antiviral therapies .

Quarterly Earnings on the Horizon

On October 15, Gilead officially announced that it will release its third-quarter 2026 earnings after market hours on Thursday, October 29, followed by a management webcast at 4:30 p.m. Eastern Time . Investors will closely monitor key metrics including revenue trends across core franchises—HIV, oncology, inflammation—and updates on newly approved treatments or late‑stage candidates.

Stock Price Context and Recent Movement

As of October 22, Gilead’s stock is trading at exactly $157.19, reflecting a 1.91% gain on that day . Over the preceding week, the stock advanced from approximately $143.21 to $151.17, equating to a weekly gain of about 5.6% . Analysts’ attention is likely divided between signals from upcoming research data and anticipation of earnings guidance.

Why This Matters to Investors

The IDWeek data presentation provides a rare glimpse into Gilead’s early-stage antiviral innovation, particularly with GS‑1179 targeting genital herpes, a leading unmet need within infectious disease treatment. Should the data be compelling, this could add long-term value to Gilead’s pipeline.

At the same time, the third-quarter earnings report may reveal whether momentum in the company’s established franchises—like Biktarvy, Trodelvy, Livdelzi, and others—continues, or whether new developments shift investor sentiment.

What to Watch Next

• Details from IDWeek 2026, especially around GS‑1179’s safety and dosing profile, and any updates on HIV or other antiviral candidates.
• Q3 2026 financials, including revenue performance by segment, earnings per share, any guidance revisions, and management commentary on pipeline advancements.
• How investors react both to clinical data and earnings, which may influence Gilead’s near-term stock trajectory and longer-term valuation.

With compelling early-stage data on the horizon and critical quarterly results soon to be revealed, Gilead stands at a strategic inflection point—balancing proven growth drivers with emerging innovation that could shape its future narrative.